211 related articles for article (PubMed ID: 30553524)
1. Amanitins and their development as a payload for antibody-drug conjugates.
Pahl A; Lutz C; Hechler T
Drug Discov Today Technol; 2018 Dec; 30():85-89. PubMed ID: 30553524
[TBL] [Abstract][Full Text] [Related]
2. Total Synthesis of α- and β-Amanitin.
Lutz C; Simon W; Werner-Simon S; Pahl A; Müller C
Angew Chem Int Ed Engl; 2020 Jul; 59(28):11390-11393. PubMed ID: 32091645
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Lerchen HG; Wittrock S; Stelte-Ludwig B; Sommer A; Berndt S; Griebenow N; Rebstock AS; Johannes S; Cancho-Grande Y; Mahlert C; Greven S; Terjung C
Angew Chem Int Ed Engl; 2018 Nov; 57(46):15243-15247. PubMed ID: 30180286
[TBL] [Abstract][Full Text] [Related]
4. Transforming toxins into treatments: the revolutionary role of α-amanitin in cancer therapy.
Ning D; Xue J; Lou X; Shao R; Liu Y; Chen G
Arch Toxicol; 2024 Jun; 98(6):1705-1716. PubMed ID: 38555326
[TBL] [Abstract][Full Text] [Related]
5. Pushing the Envelope: Advancement of ADCs Outside of Oncology.
McPherson MJ; Hobson AD
Methods Mol Biol; 2020; 2078():23-36. PubMed ID: 31643047
[TBL] [Abstract][Full Text] [Related]
6. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates- stability and formulation.
Duerr C; Friess W
Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
[TBL] [Abstract][Full Text] [Related]
8. Cleavable linkers in antibody-drug conjugates.
Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
[TBL] [Abstract][Full Text] [Related]
9. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.
Puthenveetil S; He H; Loganzo F; Musto S; Teske J; Green M; Tan X; Hosselet C; Lucas J; Tumey LN; Sapra P; Subramanyam C; O'Donnell CJ; Graziani EI
PLoS One; 2017; 12(5):e0178452. PubMed ID: 28558059
[TBL] [Abstract][Full Text] [Related]
10. Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?
Jackson PJM; Kay S; Pysz I; Thurston DE
Drug Discov Today Technol; 2018 Dec; 30():71-83. PubMed ID: 30553523
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
12. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
13. Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy.
Johnston MC; Scott CJ
Drug Discov Today Technol; 2018 Dec; 30():63-69. PubMed ID: 30553522
[TBL] [Abstract][Full Text] [Related]
14. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
15. HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.
Figueroa-Vazquez V; Ko J; Breunig C; Baumann A; Giesen N; Pálfi A; Müller C; Lutz C; Hechler T; Kulke M; Müller-Tidow C; Krämer A; Goldschmidt H; Pahl A; Raab MS
Mol Cancer Ther; 2021 Feb; 20(2):367-378. PubMed ID: 33298585
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates.
Boghaert ER; Cox MC; Vaidya KS
Cancer Res; 2022 May; 82(10):1858-1869. PubMed ID: 35298624
[TBL] [Abstract][Full Text] [Related]
17. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
18. A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists.
Mecklenburg L
Toxicol Pathol; 2018 Oct; 46(7):746-752. PubMed ID: 30295169
[TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
20. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
